CNMD 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-07-29

• On December 5, 2025, we announced our intent to exit our gastroenterology product offerings as part of our portfolio optimization strategy. This included the termination of our distribution agreement with W.L. Gore & Associates, Inc. ("Gore") for the Gore® VIABIL® biliary stent effective January 1, …

• 20262025As ReportedImpact of Foreign CurrencyConstant Currency

• Net sales increased 0.3% in the three months ended June 30, 2026 and decreased 0.5% in the six months ended June 30, 2026 compared to the same periods a year ago. During 2026, we exited the gastroenterology product offerings, impacting net sales growth. Gastroenterology sales were $4.7 million, incl…

• •Orthopedic surgery sales increased 8.2% and 7.5% in the three and six months ended June 30, 2026, respectively, primarily due to growth in our powered surgical instrument, sports medicine, visualization, and BioBrace® product offerings.

• •General surgery sales decreased 5.2% and 6.2% in the three and six months ended June 30, 2026 primarily due to the exit from many products related to gastroenterology during the three and six months ended June 30, 2026 partially offset by growth in AirSeal® and smoke evacuation product offerings.

相对上期删除的文字 · 来源:10-Q · 2026-04-30

• On December 5, 2025, we announced our intent to exit our gastroenterology product lines as part of our portfolio optimization strategy. This included the termination of our distribution agreement with W.L. Gore & Associates, Inc. ("Gore") for the Gore® VIABIL® biliary stent effective January 1, 2026…

• Net sales decreased 1.3% in the three months ended March 31, 2026 compared to the same period a year ago due to the exit from many products in the gastroenterology product line during the quarter. Gastroenterology sales were $9.5 million and $25.0 million during the three months ended March 31, 2026…

• •Orthopedic surgery sales increased 6.8% in the three months ended March 31, 2026, primarily due to growth in our procedure-specific and BioBrace® product offerings.

• •General surgery sales decreased 7.4% in the three months ended March 31, 2026 primarily due to the exit from many products in the gastroenterology product line during the quarter.

• Cost of sales decreased to $133.6 million in the three months ended March 31, 2026 as compared to $143.5 million in the three months ended March 31, 2025. Gross profit margins increased 260 basis points to 57.9% in the three months ended March 31, 2026 as compared to 55.3% in the three months ended …

相对上期新增的文字 · 来源:10-Q · 2026-07-29

• Market risk is the potential loss arising from adverse changes in market rates and prices such as commodity prices, foreign currency exchange rates and interest rates. In the normal course of business, we are exposed to various market risks,

• including changes in foreign currency exchange rates and interest rates. We manage our exposure to these and other market risks through regular operating and financing activities and as necessary through the use of derivative financial instruments.

• There have been no significant changes in our foreign currency risk exposure or in how the exposure is managed during the six months ended June 30, 2026. Reference is made to Item 7A. of our Annual Report on Form 10-K for the year ended December 31, 2025 for a description of Qualitative and Quantita…

• At June 30, 2026, we had approximately $683.0 million of variable rate debt outstanding under our senior credit agreement. Variable interest rates on our senior credit agreement are determined using a base rate of the Term Secured Overnight Financing rate plus the applicable margin. A change of 1.0%…

相对上期删除的文字 · 来源:10-Q · 2026-04-30

• There have been no significant changes in our primary market risk exposures or in how these exposures are managed during the three months ended March 31, 2026. Reference is made to Item 7A. of our Annual Report on Form 10-K for the year ended December 31, 2025 for a description of Qualitative and Qu…

相对上期新增的文字 · 来源:10-Q · 2026-07-29

• During the quarter ended June 30, 2026, none of the members of our Board of Directors or officers adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement", as each term is defined in Item 408 of Regulation S-K.

相对上期删除的文字 · 来源:10-Q · 2026-04-30

• Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory

• On April 29, 2026, Mr. Andrew Moller, Vice President, Corporate Controller and interim Principal Financial Officer of CONMED Corporation (the “Company”) notified the Company that he will depart the Company effective May 31, 2026 to pursue an opportunity with another company.

• Mr. Moller’s departure did not arise from any disagreement on any matter relating to the operations, policies, financial results or accounting practices of the Company.

• If the Company has not appointed a Chief Financial Officer on or before June 1, 2026, then Mr. Patrick J. Beyer, the Company’s President and Chief Executive Officer has been appointed the Company’s interim Principal Financial Officer following Mr. Moller’s departure and will serve until the Company …

• Biographical information about Mr. Beyer is contained in the Company’s proxy statement for its 2026 annual meeting of stockholders filed with the Securities and Exchange Commission on April 7, 2026.